Skip to content

Effect of add on therapy alpha-lipoic acid on metabolic markers in overweight PCOS patients in a tertiary care hospital: A double blind, randomized, Placebo controlled trial

Effect of add-on therapy alpha lipoic acid on insulin resistance in high body mass index polycystic ovary syndrome patients -A randomized , double -blinded , placebo-controlled trial - yes

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/07/089948
Enrollment
84
Registered
2025-07-01
Start date
Unknown
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E889- Metabolic disorder, unspecified

Interventions

Intervention1: Alpha lipoic acid: Alpha lipoic acid is a caprylic acid derived antioxidant for 12 weeks Control Intervention1: Placebo: Placebo is a starch compound will be looks similar like alpha li

Sponsors

Vijayalakshmi M
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Female patients whose bmi is above 23kg/m2 who is diagnosed with PCOS 7 taking metformin for a period 3 months

Exclusion criteria

Exclusion criteria: Breastfeeding, Lactation mothers Females affected by renal disease, liver disease, cardiac disease H/o pt taking alcohol Pcos pts who is on hormonal treatment

Design outcomes

Primary

MeasureTime frame
Improvement in Insulin sensitivity by estimating HOMA-IR from baseline to 12 weeks in overweight &obese PCOS patientsTimepoint: Improvement in Insulin sensitivity by estimating HOMA-IR from baseline to 12 weeks in overweight &obese PCOS patients

Secondary

MeasureTime frame
Improvement in liver index scores by measuring lipid accumulation product hepatic steatosis index from baseline to 12 weeksTimepoint: 12 weeks

Countries

India

Contacts

Public ContactDr Sangeetha Raja

SRM medical college hospital research instiute

sangeeta1@srmist.edu.in9176630021

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026